Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Very Nice Surprise

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 07, 2021 1:32pm

162 Views

Post# 33153377

RE:RE:RE:RE:Very Nice Surprise

Actuarial wrote: It depends on timeframe and what kind of deal Dan can bring to us. I personally prefer a bought deal though Dan mentioned partner deal is most likely.

CandyC wrote: $45-50. Dreaming. I would expect $15 by year end after NASDAQ listed

I agree.
Timing on a potential acquisition will be out a little bit - but I agree it's possible.
I think the patents will be hard for any Big Pharma to resist in the end.

We just don't know what kind of surprises they have for us this summer - could really drive excitement - especially if they can announce some new drugs and a partnership in a smaller geography (or geographies).

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages